Michelle Treitel

1.7k total citations
23 papers, 1.4k citations indexed

About

Michelle Treitel is a scholar working on Hepatology, Infectious Diseases and Molecular Biology. According to data from OpenAlex, Michelle Treitel has authored 23 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hepatology, 9 papers in Infectious Diseases and 8 papers in Molecular Biology. Recurrent topics in Michelle Treitel's work include Hepatitis C virus research (15 papers), HIV/AIDS drug development and treatment (9 papers) and Hepatitis B Virus Studies (5 papers). Michelle Treitel is often cited by papers focused on Hepatitis C virus research (15 papers), HIV/AIDS drug development and treatment (9 papers) and Hepatitis B Virus Studies (5 papers). Michelle Treitel collaborates with scholars based in United States, France and Netherlands. Michelle Treitel's co-authors include Marian Carlson, Brehon C. Laurent, Sergei Kuchin, Xinxing Yang, Francisco Estruch, Eric Hughes, Edward O’Mara, Samir K. Gupta, Fengjuan Xuan and Stephen P. Youngberg and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Gastroenterology and Molecular and Cellular Biology.

In The Last Decade

Michelle Treitel

23 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michelle Treitel United States	14	1.0k	235	233	226	139	23	1.4k
Claire Gondeau France	20	473 0.5×	261 1.1×	308 1.3×	21 0.1×	30 0.2×	32	915
Karen C. M. Moraes Brazil	14	446 0.4×	92 0.4×	64 0.3×	137 0.6×	42 0.3×	41	703
Liting Zhang China	19	731 0.7×	127 0.5×	16 0.1×	115 0.5×	32 0.2×	49	1.2k
Hiromichi Terashima Switzerland	11	542 0.5×	69 0.3×	15 0.1×	142 0.6×	55 0.4×	13	665
Jason Piotrowski United States	13	1.1k 1.1×	68 0.3×	16 0.1×	216 1.0×	36 0.3×	15	1.3k
Grant A. Bitter United States	14	652 0.6×	65 0.3×	34 0.1×	62 0.3×	84 0.6×	21	800
Dieter Vanderschaeghe Belgium	14	422 0.4×	188 0.8×	79 0.3×	146 0.6×	47 0.3×	21	739
Yongchao Cai China	11	297 0.3×	54 0.2×	109 0.5×	159 0.7×	73 0.5×	38	534
Liuyi Dang China	15	598 0.6×	71 0.3×	35 0.2×	74 0.3×	15 0.1×	33	805

Countries citing papers authored by Michelle Treitel

Since Specialization

Citations

This map shows the geographic impact of Michelle Treitel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Treitel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Treitel more than expected).

Fields of papers citing papers by Michelle Treitel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Treitel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Treitel. The network helps show where Michelle Treitel may publish in the future.

Co-authorship network of co-authors of Michelle Treitel

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Treitel. A scholar is included among the top collaborators of Michelle Treitel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Treitel. Michelle Treitel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Kao, Jia‐Horng, Ming‐Lung Yu, Chung‐Kang Peng, et al.. (2017). Daclatasvir/asunaprevir/beclabuvir, all‐oral, fixed‐dose combination for patients with chronic hepatitis C virus genotype 1. Journal of Gastroenterology and Hepatology. 32(12). 1998–2005. 9 indexed citations

2.

Hézode, Christophe, Laurent Alric, Ashley C. Brown, et al.. (2015). Randomized Controlled Trial of the NS5A Inhibitor Daclatasvir plus Pegylated Interferon and Ribavirin for HCV Genotype-4 (COMMAND-4). Antiviral Therapy. 21(3). 195–205. 18 indexed citations

3.

Hézode, Christophe, Laurent Alric, Ashley Brown, et al.. (2014). 819Daclatasvir in Combination with Peginterferon Alfa-2a and Ribavirin for Treatment-Naive Patients with HCV Genotype 4 Infection: Phase 3 COMMAND-4 Results. Open Forum Infectious Diseases. 1(suppl_1). S233–S233. 5 indexed citations

4.

Tatum, H., Paul J. Thuluvath, Eric Lawitz, et al.. (2014). A randomized, placebo‐controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1. Journal of Viral Hepatitis. 22(8). 658–664. 13 indexed citations

5.

Silva, Marcelo, Michelle Treitel, Donald J. Graham, et al.. (2013). Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3. Journal of Hepatology. 59(1). 31–37. 35 indexed citations

6.

Hulskotte, Ellen G. J., Hwa-ping Feng, Fengjuan Xuan, et al.. (2012). Pharmacokinetic Interactions Between the Hepatitis C Virus Protease Inhibitor Boceprevir and Ritonavir-Boosted HIV-1 Protease Inhibitors Atazanavir, Darunavir, and Lopinavir. Clinical Infectious Diseases. 56(5). 718–726. 58 indexed citations

7.

Treitel, Michelle, Thomas Marbury, Richard A. Preston, et al.. (2012). Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function. Clinical Pharmacokinetics. 51(9). 619–628. 34 indexed citations

8.

Howe, John A., Donald J. Graham, Patricia McMonagle, et al.. (2012). 844 IN VITRO CHARACTERIZATION OF THE PAN-GENOTYPE ACTIVITY OF THE HCV NS3/4A PROTEASE INHIBITORS BOCEPREVIR AND TELAPREVIR. Journal of Hepatology. 56. S329–S329. 2 indexed citations

9.

Bronowicki, J.-P., Mitchell Davis, S. Flamm, et al.. (2012). 11 SUSTAINED VIROLOGIC RESPONSE (SVR) IN PRIOR PEGINTERFERON/RIBAVIRIN (PR) TREATMENT FAILURES AFTER RETREATMENT WITH BOCEPREVIR (BOC)-+-PR: THE PROVIDE STUDY INTERIM RESULTS. Journal of Hepatology. 56. S6–S6. 31 indexed citations

10.

Vierling, John M., Mitchell Davis, Steven L. Flamm, et al.. (2012). 836 Sustained Virologic Response (SVR) in Prior Peginterferon/Ribavirin (PR) Treatment Failures After Retreatment With Boceprevir (BOC) + PR: the Provide Study Interim Results. Gastroenterology. 142(5). S–931. 2 indexed citations

11.

Treitel, Michelle, Thomas Marbury, Richard A. Preston, et al.. (2012). Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function. Clinical Pharmacokinetics. 51(9). 619–628. 4 indexed citations

12.

Kasserra, Claudia, Michelle Treitel, Eric Hughes, Edward O’Mara, & Jan Jaap van Lier. (2011). Effect of Boceprevir on Red Blood Cells and Markers of Anemia in Healthy Volunteers. Gastroenterology. 140(5). S–945. 1 indexed citations

13.

Bruijne, Joep de, Jean‐François Bergmann, H. W. Reesink, et al.. (2010). Antiviral Activity of Narlaprevir Combined with Ritonavir and Pegylated Interferon in Chronic Hepatitis C Patients. Hepatology. 52(5). 1590–1599. 24 indexed citations

14.

Bruijne, Joep de, Jean‐François Bergmann, Christine J. Weegink, et al.. (2010). 746 NARLAPREVIR AND PEGINTERFERON ALFA-2B FOR 2 WEEKS IN CHRONIC HEPATITIS C GENOTYPE 1 PATIENTS, FOLLOWED BY PEGINTERFERON ALFA-2B AND RIBAVIRIN FOR 24/48 WEEKS: FINAL RESULTS. Journal of Hepatology. 52. S290–S291. 2 indexed citations

15.

Fätkenheuer, Gerd, Christian Hoffmann, Jihad Slim, et al.. (2009). Short-Term Administration of the CCR5 Antagonist Vicriviroc to Patients With HIV and HCV Coinfection Is Safe and Tolerable. JAIDS Journal of Acquired Immune Deficiency Syndromes. 53(1). 78–85. 5 indexed citations

16.

Treitel, Michelle, Sergei Kuchin, & Marian Carlson. (1998). Snf1 Protein Kinase Regulates Phosphorylation of the Mig1 Repressor in Saccharomyces cerevisiae. Molecular and Cellular Biology. 18(11). 6273–6280. 268 indexed citations

17.

Estruch, Francisco, Michelle Treitel, Xinxing Yang, & Marian Carlson. (1992). N-terminal mutations modulate yeast SNF1 protein kinase function.. Genetics. 132(3). 639–650. 106 indexed citations

18.

Laurent, Brehon C., Michelle Treitel, & Marian Carlson. (1991). Functional interdependence of the yeast SNF2, SNF5, and SNF6 proteins in transcriptional activation.. Proceedings of the National Academy of Sciences. 88(7). 2687–2691. 216 indexed citations

19.

Laurent, Brehon C., Michelle Treitel, & Marian Carlson. (1990). The SNF5 Protein of Saccharomyces cerevisiae Is a Glutamine- and Proline-Rich Transcriptional Activator That Affects Expression of a Broad Spectrum of Genes. Molecular and Cellular Biology. 10(11). 5616–5625. 38 indexed citations

20.

Laurent, Brehon C., Michelle Treitel, & Marian Carlson. (1990). The SNF5 protein of Saccharomyces cerevisiae is a glutamine- and proline-rich transcriptional activator that affects expression of a broad spectrum of genes.. Molecular and Cellular Biology. 10(11). 5616–5625. 124 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact